drugset / Trial / NCT01029925

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

NCT01029925

Phase 2 Terminated 7 enrolled Jonsson Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the response rate by RECIST criteria of oral dichloroacetate in patients with recurrent and/or metastatic and pretreated breast and non-small cell lung cancer.

Timeline

Start
2009-12
Primary completion
2011-08
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dichloroacetate Small molecule 6.25 mg/kg Oral